NASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free ATAI Stock Alerts $1.85 -0.12 (-6.09%) (As of 11:58 AM ET) Add Compare Share Share Today's Range$1.85▼$1.9650-Day Range$1.63▼$2.6052-Week Range$1.03▼$2.85Volume464,069 shsAverage Volume1.71 million shsMarket Capitalization$307.16 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atai Life Sciences alerts: Email Address Atai Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside460.0% Upside$10.50 Price TargetShort InterestHealthy4.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 6 Articles This WeekInsider TradingSelling Shares$164,742 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.80) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.90 out of 5 starsMedical Sector385th out of 909 stocksPharmaceutical Preparations Industry171st out of 423 stocks 3.5 Analyst's Opinion Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.81% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Atai Life Sciences has recently increased by 6.53%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATAI. Previous Next 3.2 News and Social Media Coverage News SentimentAtai Life Sciences has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Atai Life Sciences this week, compared to 2 articles on an average week.Search InterestOnly 23 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows20 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,742.00 in company stock.Percentage Held by Insiders30.00% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atai Life Sciences are expected to grow in the coming year, from ($0.80) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -6.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 1.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Atai Life Sciences Stock (NASDAQ:ATAI)ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and developing various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its principal clinical programs include RL-007, a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; GRX-917, a deuterated etifoxine for anxiety disorders; VLS-01 a N,N-Dimethyltryptamine for treatment resistant depression (TRD); DMX-1002, an oral formulation of ibogaine, a cholinergic, glutamatergic and monoaminergic receptor modulator that is a naturally occurring psychedelic product isolated from a West African shrub for the treatment of opioid use disorders (OUD); and EMP-01, an oral formulation of an MDMA derivative being developed for the treatment of post-traumatic stress disorder. The company's other clinical programs comprise PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; and KUR-101, a formulation of deuterated mitragynine for the treatment of OUD. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More ATAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATAI Stock News HeadlinesApril 24, 2024 | proactiveinvestors.comatai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression studyApril 24, 2024 | finance.yahoo.comatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 24, 2024 | globenewswire.comatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionApril 18, 2024 | stockhouse.comatai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyApril 18, 2024 | investing.comatai Life Sciences reports positive Phase 1 results for BPL-003April 17, 2024 | finance.yahoo.comatai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyApril 17, 2024 | proactiveinvestors.comatai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT assetApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 17, 2024 | msn.comAtai Life Sciences N.V. (ATAI) Price Target Decreased by 15.35% to 10.90April 15, 2024 | proactiveinvestors.comatai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalystsApril 6, 2024 | investing.comAtai Life Sciences executive sells $114k in company stockApril 4, 2024 | msn.comAre You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great ChoiceApril 3, 2024 | msn.comAtai Life Sciences upgraded at Maxim on Beckley investmentApril 2, 2024 | msn.comUT Tyler University Academy senior directs first student-led theater productionApril 1, 2024 | msn.comCould We Ever Have Sci-Fi Tech Like the ‘Star Trek’ Transporter? A New Roddenberry Entertainment Podcast Finds OutApril 1, 2024 | finance.yahoo.comAtai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 29, 2024 | msn.comAtai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic PipelineMarch 28, 2024 | msn.comIntranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionMarch 28, 2024 | benzinga.comRecap: ATAI Life Sciences Q4 EarningsMarch 28, 2024 | proactiveinvestors.comatai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapiesMarch 28, 2024 | msn.comATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04March 28, 2024 | globenewswire.comatai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsMarch 27, 2024 | proactiveinvestors.comatai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression studyMarch 27, 2024 | markets.businessinsider.comAtai Life: Beckley Psytech's Phase 2a Trial Of BPL-003 Positive In Treatment Resistant DepressionMarch 27, 2024 | finance.yahoo.comatai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionMarch 27, 2024 | globenewswire.comatai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant DepressionSee More Headlines Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees133Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+433.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,220,000.00 Net Margins-12,810.51% Pretax Margin-12,511.46% Return on Equity-45.08% Return on Assets-38.46% Debt Debt-to-Equity Ratio0.08 Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$310,000.00 Price / Sales1,055.09 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.34Miscellaneous Outstanding Shares166,030,000Free Float116,218,000Market Cap$327.08 million OptionableOptionable Beta0.98 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Christian Angermayer (Age 46)Founder & Chairman of the Supervisory Board Comp: $70kMr. Florian Brand (Age 37)Co-founder & CEO Comp: $835.44kDr. Srinivas G. Rao M.D. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Comp: $834.15kMr. Stephen B. Bardin (Age 33)Advisor Comp: $651.32kMs. Anne JohnsonChief Financial OfficerDr. Michael Raven Ph.D.Senior Vice President of OperationsMr. Frank Stegert (Age 43)Vice President of Investment & Venture Management Mr. Ryan Barrett (Age 43)Senior VP, General Counsel & Corporate Secretary Dr. Glenn Short Ph.D.Senior Vice President of Early DevelopmentDr. Sahil V. Kirpekar M.D. (Age 38)Chief Business Officer More ExecutivesKey CompetitorsRani TherapeuticsNASDAQ:RANIAtea PharmaceuticalsNASDAQ:AVIRAquestive TherapeuticsNASDAQ:AQSTUroGen PharmaNASDAQ:URGNMereo BioPharma GroupNASDAQ:MREOView All CompetitorsInsiders & InstitutionsQuattro Financial Advisors LLCBought 70,976 shares on 4/18/2024Ownership: 0.043%CRA Financial Services LLCBought 12,903 shares on 4/17/2024Ownership: 0.008%Kingswood Wealth Advisors LLCBought 30,000 shares on 4/15/2024Ownership: 0.018%Srinivas RaoSold 61,640 sharesTotal: $114,034.00 ($1.85/share)Anne Nagengast JohnsonSold 27,410 sharesTotal: $50,708.50 ($1.85/share)View All Insider TransactionsView All Institutional Transactions ATAI Stock Analysis - Frequently Asked Questions Should I buy or sell Atai Life Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks. What is Atai Life Sciences' stock price target for 2024? 3 Wall Street research analysts have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $6.00 to $15.00. On average, they predict the company's stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 460.0% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts. How have ATAI shares performed in 2024? Atai Life Sciences' stock was trading at $1.41 at the beginning of 2024. Since then, ATAI shares have increased by 33.0% and is now trading at $1.8750. View the best growth stocks for 2024 here. Are investors shorting Atai Life Sciences? Atai Life Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,550,000 shares, an increase of 6.5% from the March 15th total of 5,210,000 shares. Based on an average trading volume of 1,740,000 shares, the short-interest ratio is currently 3.2 days. Approximately 4.8% of the company's stock are short sold. View Atai Life Sciences' Short Interest. When is Atai Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ATAI earnings forecast. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) released its quarterly earnings data on Thursday, March, 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.17) by $0.05. The firm earned $0.02 million during the quarter, compared to the consensus estimate of $0.90 million. Atai Life Sciences had a negative trailing twelve-month return on equity of 45.08% and a negative net margin of 12,810.51%. What ETF holds Atai Life Sciences' stock? AdvisorShares Psychedelics ETF holds 187,558 shares of ATAI stock, representing 5.86% of its portfolio. What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO). When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Quattro Financial Advisors LLC (0.04%), Kingswood Wealth Advisors LLC (0.02%) and CRA Financial Services LLC (0.01%). Insiders that own company stock include Anne Nagengast Johnson, Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATAI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingPrepare for a recession unlike any otherAmerican Hartford Gold GroupExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
